Elizabeth C Finger1, Julia MacKinley2, Mervin Blair2, Lindsay D Oliver2, Sarah Jesso2, Maria C Tartaglia2, Michael Borrie2, Jennie Wells2, Isabel Dziobek2, Stephen Pasternak2, Derek G V Mitchell2, Katherine Rankin2, Andrew Kertesz2, Adam Boxer2. 1. From the Departments of Clinical Neurological Sciences (E.C.F., J.M., M.B., S.J., S.P., A.K.), Medicine (M.B., J.W.), Psychiatry (D.G.V.M.), and Anatomy and Cell Biology (D.G.V.M.), and Graduate Program in Neuroscience (L.D.O.), Schulich School of Medicine and Dentistry, Western University, London, Ontario; Tanz Centre for Research in Neurodegenerative Disease (M.C.T.), University of Toronto, Canada; Freie Universität Berlin (I.D.), Cluster of Excellence Languages of Emotion, Berlin, Germany; and Department of Neurology (K.R., A.B.), University of California San Francisco School of Medicine. Elizabeth.Finger@lhsc.on.ca. 2. From the Departments of Clinical Neurological Sciences (E.C.F., J.M., M.B., S.J., S.P., A.K.), Medicine (M.B., J.W.), Psychiatry (D.G.V.M.), and Anatomy and Cell Biology (D.G.V.M.), and Graduate Program in Neuroscience (L.D.O.), Schulich School of Medicine and Dentistry, Western University, London, Ontario; Tanz Centre for Research in Neurodegenerative Disease (M.C.T.), University of Toronto, Canada; Freie Universität Berlin (I.D.), Cluster of Excellence Languages of Emotion, Berlin, Germany; and Department of Neurology (K.R., A.B.), University of California San Francisco School of Medicine.
Abstract
OBJECTIVE: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). METHODS: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia (clinicaltrials.gov registration number NCT01386333). Primary outcome measures were safety and tolerability at each dose. Secondary measures explored efficacy across the combined oxytocin vs placebo groups and examined potential dose-related effects. RESULTS: All 3 doses of intranasal oxytocin were safe and well tolerated. CONCLUSIONS: A multicenter trial is warranted to determine the therapeutic efficacy of long-term intranasal oxytocin for behavioral symptoms in FTD. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with FTD, intranasal oxytocin is not significantly associated with adverse events or significant changes in the overall neuropsychiatric inventory.
RCT Entities:
OBJECTIVE: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). METHODS: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia (clinicaltrials.gov registration number NCT01386333). Primary outcome measures were safety and tolerability at each dose. Secondary measures explored efficacy across the combined oxytocin vs placebo groups and examined potential dose-related effects. RESULTS:All 3 doses of intranasal oxytocin were safe and well tolerated. CONCLUSIONS: A multicenter trial is warranted to determine the therapeutic efficacy of long-term intranasal oxytocin for behavioral symptoms in FTD. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with FTD, intranasal oxytocin is not significantly associated with adverse events or significant changes in the overall neuropsychiatric inventory.
Authors: D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson Journal: Neurology Date: 1998-12 Impact factor: 9.910
Authors: Inga D Neumann; Rodrigue Maloumby; Daniela I Beiderbeck; Michael Lukas; Rainer Landgraf Journal: Psychoneuroendocrinology Date: 2013-04-08 Impact factor: 4.905
Authors: Erin C McKay; John S Beck; Sok Kean Khoo; Karl J Dykema; Sandra L Cottingham; Mary E Winn; Henry L Paulson; Andrew P Lieberman; Scott E Counts Journal: J Neuropathol Exp Neurol Date: 2019-05-01 Impact factor: 3.685
Authors: Mijail D Serruya; James P Harris; Dayo O Adewole; Laura A Struzyna; Justin C Burrell; Ashley Nemes; Dmitriy Petrov; Reuben H Kraft; H Isaac Chen; John A Wolf; D Kacy Cullen Journal: Adv Funct Mater Date: 2017-09-04 Impact factor: 18.808
Authors: Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Davide Seripa; Antonio Daniele; Mark Watling; Gianluigi Giannelli Journal: Nat Rev Neurol Date: 2020-03-23 Impact factor: 42.937